Eleonora Teplinsky, MD
Head of Breast and Gynecologic Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care
Medical School
Tufts University School of Medicine, Boston, MA
Residency
Internal Medicine at Tufts Medical Center, Boston, MA
Fellowship(s)
Hematology/Oncology at NYU Langone Medical Center, New York, NY
Area of Expertise
- Breast Oncology
- Gynecologic Oncology
- Young Women with Breast Cancer
- Cancer Survivorship
- Social Media in Oncology
Years of Experience
Over 10 years
Certifications & Licensure
- Board-Certified in Internal Medicine
- Board-Certified in Medical Oncology
- New Jersey Medical License
Biography
Dr. Eleonora Teplinsky is a board-certified medical oncologist specializing in breast and gynecologic oncology. She serves as the Head of Breast and Gynecologic Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, NJ, and holds a position as Clinical Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.
With a career spanning over 15 years, Dr. Teplinsky has dedicated her expertise to improving the lives of cancer patients. Her clinical and research interests extend to cancer survivorship and the innovative use of social media in oncology. Dr. Teplinsky is passionate about oncology education and advocacy, actively engaging on social media platforms under the handle @drteplinsky.
In addition to her clinical work, Dr. Teplinsky serves on the medical advisory board of Living Beyond Breast Cancer and is a frequent media contributor. She hosts the INTERLUDE Podcast, sharing stories and experiences of those affected by cancer, further demonstrating her commitment to patient education and support.
Awards, Honors & Recognitions
- Healthcare Hero, NJ Biz Health Care Heroes Program – August 2022
- Medical Honoree, American Cancer Society Diamond Ball, Westmount, NJ – October 2022
- 2023 Healio Disrupter Innovator Award – Social Media Influencer, Healio HemOnc Today – June 2023
Publications
- Balk E, Teplinsky E, Trikalinos T, Chew P, Chung M, Lau J, Pittas A. Applicability of the Evidence Regarding Intensive Glycemic Control and Self-Monitored Blood Glucose to Medicare Patients with Type 2 Diabetes. Agency for Healthcare Research and Quality (AHRQ). Health Technology Assessment Database. 2007.
- Raman G, Chew P, Trikalinos T, Teplinsky E, DeVine D, Demmer L, Lau J. Genetic Tests for Non-Cancer Conditions. Agency for Healthcare Research and Quality (AHRQ). Health Technology Assessment Database. 2008 Issue 3, John Wiley & Sons, Ltd. Chichester UK. Division: ST.
- Teplinsky E, Cheung D, Weisberg I, Jacobs RE, Wolff M, Park J, Friedman K, Muggia F, Jhaveri K. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat. 2013; 141(2):167-172.
- Teplinsky E, Jhaveri K. Antibody-drug conjugates and T-DM1. Contemporary Oncology. 2014; 6(1): 24-30.
- Teplinsky E, Blank S, Muggia F. Epidermal growth factor receptor: will it ever become a therapeutic target in ovarian cancer? Transl Cancer Res 2014;3(2): 119-123.
- Teplinsky E, Muggia F. Targeting HER2 in Ovarian and Uterine Cancers: Challenges & Future Directions. Gynecologic Oncology 2014; 135(2): 364-70.
- Teplinsky E, Muggia F. EGFR & HER2: is there a role in ovarian cancer? Transl Cancer Res 2015; 4(1): 107-117.
- Kudlowitz D, Teplinsky E, Muggia F. Integrating targeted drugs with taxanes and platinums: opportunities and challenges. Transl Cancer Res 2015; 4 (1): 127-136.
- Jhaveri K*, Teplinsky E*, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine P, Hashmi S, Zolfaghari L, Hoffman H, Singh B, Goldberg J, Hochman T, Formenti S, Esteva F, Moran M, Schneider R. Hyperactivated mTOR and JAK2/STAT3 pathways: crucial molecular drivers and potential therapeutic targets of inflammatory breast Cancer and locally advanced breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 2016; 16(2): 113-122.
*Both authors have equal contribution. - Benedict C, Thom B, Teplinsky E, Carleton J, Kelvin JF. Family-building after breast cancer: considering the impact on adherence to adjuvant endocrine therapy. Clin Breast Cancer 2017; 17(3): 165-244.
- Teplinsky E, Herzog TJ. The efficacy of trabectedin in treating ovarian cancer. Expert Opin Pharmacother 2017; 18(3): 313-323.
- Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D’Andrea GD, Adams S, Patil S, Haque S, O’Neill T, Friedman K, Esteva FJ, Hudis C, Modi S. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER) positive metastatic breast cancer. Breast Cancer Res 2017; 19(1):89.
- Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA 3rd. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 Jan 10;39(2):155-169. doi: 10.1200/JCO.20.02953. Epub 2020 Dec 8. PMID: 33290128.
- Tufano AM, Teplinsky E, Landry CA. Updates in neoadjuvant therapy for triple negative breast cancer. Clin Breast Cancer. 2021 Feb;21(1):1-9. doi: 10.1016/j.clbc.2020.07.001. Epub 2020 Jul 3. PMID: 32800492.
- Beltrán Ponce S, Barry MM, Dizon DS, Katz MS, Murphy M, Teplinsky E, Tinianov S, Attai DJ, Markham MJ. Netiquette for social media engagement for oncology professionals. Future Oncol. 2022 Mar;18(9):1133-1141.
- Teplinsky E, Beltrán Ponce S, Drake EK, Garcia AM, Loeb S, van Londen GJ, Teoh D, Thompson M, Schapira L, Collaboration for Outcomes Using Social Media in Oncology (COSMO). Online Medical Misinformation in Cancer: Distinguishing Fact from Fiction. JCO Oncol Pract. 2022 Aug;18(8): 584-589.
- Ponce SB, McAlarnen L, Teplinsky E. The Challenges of Reaching Cancer Patients on Social Media: Lessons from the Failed #CancerRealTalk Experience. JCO Oncol Pract. 2023 Feb;19(2):63-65.
- Mittal K, Sheen M, Wheelden M, Faramand R, Teplinsky E, Joshi M. Dobbs vs Jackson – Rewriting Women’s Autonomy in Cancer Care. JCO Oncol Pract. 2023 April;19(4):157-159.
- Bhardwaj P, Gupta S, Elyash A, Teplinsky E. Male Breast Cancer: A Review on Diagnosis, Treatment and Survivorship. Curr Oncol Rep, 2024 Jan; 26(1): 34-45.
- Kaufman R, Agrawal L, Teplinsky E, Kiel L, Abioye O, Florez, N. From diagnosis to survivorship addressing the sexual health of women during cancer. In review to The Oncologist, submitted June 2024.
- Hutchcraft ML, Rios-Doria E, Sia TY, Teplinsky E, Westin SN, Nelson G. #HastagThis- Everything you need to know about launching your gynecologic oncology social media research career: A report from Gynecologic Oncology Reports and Society of Gynecologic Oncology Education Committee. Gynecol Oncol Rep. 2024 Jul 5:54:101451.
featured Articles
your Tumor
Understand the genomics of your tumor and what it means for breast cancer treatment.
The Fundamentals of Genomic Testing in Breast Cancer
Discover the fundamentals of genomic testing in breast cancer.
The DEBRA Trial and MammaPrint’s Role
The DEBRA Trial explores reducing radiation after surgery.
Featured Interview
Breakthroughs in Breast Cancer Treatment Testing
Testimonial
Latest News & Resources
News
Patient Resources
MEET OUR EXPERT MEDICAL TEAM
Explore the expertise of our medical advisors, who are dedicated to advancing breast cancer awareness, treatment, and support. Connect with our team and discover how their guidance contributes to the resources and insights available within our breast cancer support groups.
